abstract: Importance: @entity6 ( @entity6 ) affects as many as 40% of @entity0 undergoing surgery and is associated with increased all-cause mortality. @entity5 ( @entity5 ) is a well-known risk factor for cardiovascular mortality. Objective: To determine the association between @entity2 and long-term cardiovascular-specific mortality after vascular surgery. Design, Setting, and @entity0 : A single-center cohort of 3646 @entity0 underwent inpatient vascular surgery from January 1, 2000, to November 30, 2010, at a tertiary care teaching hospital. To determine cause-specific mortality for @entity0 undergoing vascular surgery, a proportional subdistribution hazards regression analysis was used to model long-term cardiovascular-specific mortality while treating any other cause of @entity4 as a competing risk. @entity2 constituted the main covariate after adjusting for baseline @entity0 characteristics, surgery type, and admission hemoglobin level. Final follow-up was completed July 2014 to assess survival through January 31, 2014, and data were analyzed from June 1, 2014, to September 7, 2015. Main Outcomes and Measures: Perioperative @entity6 , presence of @entity5 , and overall and cause-specific mortality. Results: Among the 3646 @entity0 undergoing vascular surgery, perioperative @entity6 occurred in 1801 (49.4%) and @entity5 was present in 496 (13.6%). The top 2 causes among the 1577 @entity4 in our cohort were @entity3 (845 of 1577 [53.6%]) and @entity1 (173 of 1577 [11.0%]). Adjusted cardiovascular mortality estimates at 10 years were 17%, 31%, 30%, and 41%, respectively, for @entity0 with no @entity2 , @entity6 without @entity5 , @entity5 without @entity6 , and @entity6 with @entity5 . Adjusted hazard ratios (95% CIs) for cardiovascular mortality were significantly elevated among @entity0 with @entity6 without @entity5 (2.07 [1.74-2.45]), @entity5 without @entity6 (2.01 [1.46-2.78]), and @entity6 with @entity5 (2.99 [2.37-3.78]) and were higher than those for other risk factors, including increasing age (1.03 per 1-year increase; 1.02-1.04), emergent surgery (1.47; 1.27-1.71), and admission hemoglobin levels lower than 10 g/dL (1.39; 1.14-1.69) compared with a hemoglobin level of 12 g/dL or higher. Conclusions and Relevance: Perioperative @entity6 is common in @entity0 undergoing vascular surgery and is associated with a high risk for cardiovascular-specific mortality comparable to that seen with @entity5 . These findings reinforce the importance of preoperative and postoperative risk stratification for @entity2 and the implementation of strategies now available to help prevent perioperative @entity6 .

title: Cardiovascular-Specific Mortality and XXXX in @entity0 Undergoing Vascular Surgery.

answer: @entity2


abstract: Importance: @entity6 ( @entity6 ) affects as many as 40% of @entity0 undergoing surgery and is associated with increased all-cause mortality. @entity5 ( @entity5 ) is a well-known risk factor for cardiovascular mortality. Objective: To determine the association between @entity2 and long-term cardiovascular-specific mortality after vascular surgery. Design, Setting, and @entity0 : A single-center cohort of 3646 @entity0 underwent inpatient vascular surgery from January 1, 2000, to November 30, 2010, at a tertiary care teaching hospital. To determine cause-specific mortality for @entity0 undergoing vascular surgery, a proportional subdistribution hazards regression analysis was used to model long-term cardiovascular-specific mortality while treating any other cause of @entity4 as a competing risk. @entity2 constituted the main covariate after adjusting for baseline @entity0 characteristics, surgery type, and admission hemoglobin level. Final follow-up was completed July 2014 to assess survival through January 31, 2014, and data were analyzed from June 1, 2014, to September 7, 2015. Main Outcomes and Measures: Perioperative @entity6 , presence of @entity5 , and overall and cause-specific mortality. Results: Among the 3646 @entity0 undergoing vascular surgery, perioperative @entity6 occurred in 1801 (49.4%) and @entity5 was present in 496 (13.6%). The top 2 causes among the 1577 @entity4 in our cohort were @entity3 (845 of 1577 [53.6%]) and @entity1 (173 of 1577 [11.0%]). Adjusted cardiovascular mortality estimates at 10 years were 17%, 31%, 30%, and 41%, respectively, for @entity0 with no @entity2 , @entity6 without @entity5 , @entity5 without @entity6 , and @entity6 with @entity5 . Adjusted hazard ratios (95% CIs) for cardiovascular mortality were significantly elevated among @entity0 with @entity6 without @entity5 (2.07 [1.74-2.45]), @entity5 without @entity6 (2.01 [1.46-2.78]), and @entity6 with @entity5 (2.99 [2.37-3.78]) and were higher than those for other risk factors, including increasing age (1.03 per 1-year increase; 1.02-1.04), emergent surgery (1.47; 1.27-1.71), and admission hemoglobin levels lower than 10 g/dL (1.39; 1.14-1.69) compared with a hemoglobin level of 12 g/dL or higher. Conclusions and Relevance: Perioperative @entity6 is common in @entity0 undergoing vascular surgery and is associated with a high risk for cardiovascular-specific mortality comparable to that seen with @entity5 . These findings reinforce the importance of preoperative and postoperative risk stratification for @entity2 and the implementation of strategies now available to help prevent perioperative @entity6 .

title: Cardiovascular-Specific Mortality and @entity2 in XXXX Undergoing Vascular Surgery.

answer: @entity0


abstract: AIM: This study aims to evaluate the clinical efficacy and safety of intravenous Cefoselis injection for the treatment of acute moderate and severe @entity5 . @entity0 AND METHODS: A multicenter, double-blind, randomized clinical trial was carried out using Cefepime as control. @entity0 received 1.0 g of either Cefoselis or Cefepime for moderate @entity1 or 2.0 g for severe @entity1 at an interval of 12 hours for 7 to 14 days. A total of 276 @entity0 (138 with Cefoselis, 138 with Cefepime) with @entity4 were enrolled in the study. Up to 137 and 124 @entity0 receiving Cefoselis and 132 and 125 @entity0 receiving Cefepime were eligible for the ITT (intent to treat) and PP (per protocol) analyses, respectively. RESULTS: At the end of the treatment, the cure rates and effective rates were 59.68% (74/124) and 93.55% (116/124) with Cefoselis, and 56.00% (74/124) and 90.40% (116/124) with Cefepime. The bacterial eradication rates of the two groups were 90.32% and 93.85%, respectively. No statistical differences were observed on the above-mentioned parameters between the two groups (all p > 0.05). Adverse events, mainly mild aminotransferase elevation and mild @entity3 , were observed in 11.59% (16/138) and 13.77% (19/138) of @entity0 with Cefoselis and @entity6 , respectively (p > 0.05). CONCLUSIONS: Cefoselis is an effective and safe choice against acute moderate and severe @entity4 and @entity2 ( @entity2 ).

title: Multicenter, double-blind, randomized clinical trial of parenterally administered Cefoselis versus Cefepime for the treatment of acute XXXX .

answer: @entity5


abstract: OBJECTIVE: The present double-blind randomized clinical trial aimed to compare the efficacy in reducing dentin @entity1 of a dentifrice formulation containing nano- @entity2 with a @entity3 dentifrice and a placebo. METHOD AND MATERIALS: 105 subjects were recruited to participate in the study. A computer-generated random table with blocking to one of the three study treatments was used in order to have 35 subjects per group: 1) nano- @entity2 15% toothpaste, @entity3 -free; 2) @entity3 toothpaste; 3) placebo. Groups 1, 2, and 3 were instructed to brush their teeth for 2 minutes twice a day with the provided toothpaste. The @entity0 's dentin @entity1 was evaluated at baseline and after 2 and 4 weeks using airblast and tactile tests. In addition, a subjective evaluation using a visual analog scale (VAS) was used. RESULTS: Significantly lower values of cold air sensitivity and tactile sensitivity (P<.001) were found for the test group at 2 weeks and 4 weeks. In addition, statistically significantly (P<.001) lower values of sensitivity were reported for group 1 compared to groups 2 and 3, at 2 and 4 weeks respectively. The VAS scores were significantly lower (P<.001) in the test group at 2 and 4 weeks compared to baseline and to the control groups. CONCLUSION: The findings of the present study encourage the application of nano- @entity2 in @entity3 -free toothpaste as an effective desensitizing agent providing quick relief from symptoms after 2 and 4 weeks.

title: Effectiveness of nano- @entity2 toothpaste in reducing dentin XXXX : a double-blind randomized controlled trial.

answer: @entity1


abstract: OBJECTIVE: The present double-blind randomized clinical trial aimed to compare the efficacy in reducing dentin @entity1 of a dentifrice formulation containing nano- @entity2 with a @entity3 dentifrice and a placebo. METHOD AND MATERIALS: 105 subjects were recruited to participate in the study. A computer-generated random table with blocking to one of the three study treatments was used in order to have 35 subjects per group: 1) nano- @entity2 15% toothpaste, @entity3 -free; 2) @entity3 toothpaste; 3) placebo. Groups 1, 2, and 3 were instructed to brush their teeth for 2 minutes twice a day with the provided toothpaste. The @entity0 's dentin @entity1 was evaluated at baseline and after 2 and 4 weeks using airblast and tactile tests. In addition, a subjective evaluation using a visual analog scale (VAS) was used. RESULTS: Significantly lower values of cold air sensitivity and tactile sensitivity (P<.001) were found for the test group at 2 weeks and 4 weeks. In addition, statistically significantly (P<.001) lower values of sensitivity were reported for group 1 compared to groups 2 and 3, at 2 and 4 weeks respectively. The VAS scores were significantly lower (P<.001) in the test group at 2 and 4 weeks compared to baseline and to the control groups. CONCLUSION: The findings of the present study encourage the application of nano- @entity2 in @entity3 -free toothpaste as an effective desensitizing agent providing quick relief from symptoms after 2 and 4 weeks.

title: Effectiveness of nano- XXXX toothpaste in reducing dentin @entity1 : a double-blind randomized controlled trial.

answer: @entity2


abstract: @entity7 is a @entity8 endemic to the desert regions of the southwestern United States, Mexico, Central America, and South America. The incidence of reported disease increased substantially between 1998 and 2011, and the @entity5 is encountered beyond the endemic areas because of a mobile society. The disease is caused by inhalation of spores of Coccidioides species. Individuals at high risk are those exposed to frequent soil aerosolization. The diagnosis is established by direct visualization of mature spherules by using special stains or cultures from biologic specimens. Serologic testing of anticoccidioidal antibodies is used for diagnosis and treatment monitoring. The @entity5 is self-limited in 60% of cases. When the disease is symptomatic, the lung is the primary site of involvement. On the basis of clinical presentation and imaging abnormalities, @entity7 is categorized into acute, disseminated, and chronic forms, each with a spectrum of imaging findings. In @entity0 with @entity10 , the most common findings are lobar or segmental consolidation, multifocal consolidation, and nodules. Adenopathy and @entity12 are also seen, usually in association with parenchymal disease. @entity3 is rare and occurs in less than 1% of @entity0 . Pulmonary findings are miliary nodules and confluent parenchymal opacities. Acute @entity9 is an infrequent complication of disseminated disease. The acute findings resolve in most @entity0 , with chronic changes developing in approximately 5% of @entity0 . Manifestations of @entity4 include residual nodules, chronic @entity13 , persistent @entity2 with or without adenopathy, @entity12 , and regressive changes. Unusual complications of @entity4 are @entity14 , @entity11 formation, and @entity6 . @entity0 in an immunocompromised state, those with @entity1 , pregnant @entity0 , and those belonging to certain ethnic groups may show severe, progressive, or disseminated disease.

title: XXXX : pictorial review of chest radiographic and CT findings.

answer: @entity7


abstract: @entity12 in @entity0 are rare, are more commonly benign, and differ in types when compared with those in adults. @entity13 , @entity2 , and @entity3 are the most common @entity12 in fetuses and neonates. In @entity0 and @entity0 , the most common @entity12 are @entity13 and @entity3 , which are benign primary @entity12 , whereas in adults, @entity7 is the most common cardiac mass and @entity10 is the most common primary @entity12 . @entity4 are the most common primary @entity12 in both @entity0 and adults. Metastatic @entity12 are less common in @entity0 than in adults and include @entity4 , @entity5 , @entity1 , and @entity11 . @entity0 with @entity12 can be asymptomatic or may present with murmur, @entity8 , @entity6 , or @entity9 . Echocardiography is the primary modality for initial evaluation of symptomatic @entity0 . Cardiac magnetic resonance imaging provides further characterization of cardiac masses and @entity1 for diagnostic purposes and can be used to assess cardiac and extracardiac involvement for treatment planning. Treatment varies from conservative management or surgical resection to transplantation, depending on the diagnosis and the @entity0 's symptoms. @entity13 typically regresses spontaneously during early childhood and does not require surgical intervention if asymptomatic. However, @entity3 is generally resected because it does not regress. An understanding of the types of @entity12 that occur in @entity0 and @entity0 , their clinical implications and associations, and their imaging appearances will facilitate @entity0 management.

title: XXXX : clinical and imaging features.

answer: @entity12


abstract: BACKGROUND: @entity0 with @entity2 ( @entity2 ) have @entity1 in @entity3 ( @entity3 ) and central coherence (CC) consistent with an inflexible thinking style and overly detailed processing style, respectively. This study investigates brain activation during @entity3 and CC tasks in @entity0 with @entity2 and tests whether this activation is a biomarker that predicts response to treatment. METHODS: FMRI data were collected from 21 females with @entity2 while performing an @entity3 task (the Wisconsin Card Sort) and a CC task (embedded figures), and used to predict outcome following 16 weeks of treatment (either 16 weeks of cognitive behavioral therapy or 8 weeks cognitive remediation therapy followed by 8 weeks of cognitive behavioral therapy). RESULTS: Significant activation during the @entity3 task included bilateral dorsolateral and ventrolateral prefrontal cortex and left anterior middle frontal gyrus. Higher scores on the neuropsychological test of @entity3 (measured outside the scanner at baseline) were correlated with greater DLPFC and VLPFC/insula activation. Improvements in @entity3 following treatment were significantly predicted by a combination of low VLPFC/insula and high anterior middle frontal activation (R squared  =  .68, p  =  .001). For the CC task, visual and parietal cortical areas were activated, but were not significantly correlated with neuropsychological measures of CC and did not predict outcome. CONCLUSION: Cognitive flexibility requires the support of several prefrontal cortex resources. As previous studies suggest that the VLPFC is important for selecting context-appropriate responses, @entity0 who have difficulties with this skill may benefit the most from cognitive therapy with or without cognitive remediation therapy. The ability to sustain inhibition of an unwanted response, subserved by the anterior middle frontal gyrus, is a cognitive feature that predicts favorable outcome to cognitive treatment. @entity1 may not be an effective predictor of clinical outcome.

title: Predicting clinical outcome using brain activation associated with set-shifting and central coherence skills in XXXX .

answer: @entity2


abstract: BACKGROUND: Age, estimated @entity1 ( @entity2 ), and ejection fraction are preprocedural predictors of contrast-induced @entity3 (CI-AKI) after primary percutaneous coronary intervention. The effect of renal function-adjusted contrast volume (CV) remains not totally explored, and a threshold has not yet been established. METHODS AND RESULTS: Logistic regression and receiver-operating characteristic curve analyses were used to assess whether CV/ @entity2 was an independent predictor of CI-AKI. The increased discriminative value of CV/ @entity2 over the preprocedural model based on age, @entity2 , and ejection fraction was examined using the net reclassification improvement analysis. Of 470 @entity0 enrolled, we observed 25 (5.3%) cases of CI-AKI. @entity0 with CI-AKI had received a higher renal function-adjusted CV (CV/ @entity2 3.62 versus 1.96; P<0.001), and CI-AKI incidence was higher (15%; P<0.001) in @entity0 in the highest quartile of CV/ @entity2 , corresponding to the cutoff indicated by the receiver-operating characteristic curve (>2.5; area under the curve, 0.77). At multivariable analysis, CV/ @entity2 above the cutoff (odds ratio, 5.57; P=0.002) remained an independent predictor of CI-AKI. The model with CV/ @entity2 demonstrated a statistically significantly net reclassification improvement of 0.23 (P=0.021) over the baseline preprocedural model, largely driven by a correct decrease in risk estimates for @entity0 not experiencing CI-AKI, with a likelihood ratio   (2) of 5.973 (P=0.029). CONCLUSIONS: CV remains a key risk factor for CI-AKI after primary percutaneous coronary intervention and our study supports the need for minimizing CV, independently from baseline preprocedural risk. A CV restricted to no more than twice and a half the baseline @entity2 might be valuable in reducing the risk of CI-AKI.

title: Renal function-adjusted contrast volume redefines the baseline estimation of contrast-induced XXXX risk in @entity0 undergoing primary percutaneous coronary intervention.

answer: @entity3


abstract: BACKGROUND: Age, estimated @entity1 ( @entity2 ), and ejection fraction are preprocedural predictors of contrast-induced @entity3 (CI-AKI) after primary percutaneous coronary intervention. The effect of renal function-adjusted contrast volume (CV) remains not totally explored, and a threshold has not yet been established. METHODS AND RESULTS: Logistic regression and receiver-operating characteristic curve analyses were used to assess whether CV/ @entity2 was an independent predictor of CI-AKI. The increased discriminative value of CV/ @entity2 over the preprocedural model based on age, @entity2 , and ejection fraction was examined using the net reclassification improvement analysis. Of 470 @entity0 enrolled, we observed 25 (5.3%) cases of CI-AKI. @entity0 with CI-AKI had received a higher renal function-adjusted CV (CV/ @entity2 3.62 versus 1.96; P<0.001), and CI-AKI incidence was higher (15%; P<0.001) in @entity0 in the highest quartile of CV/ @entity2 , corresponding to the cutoff indicated by the receiver-operating characteristic curve (>2.5; area under the curve, 0.77). At multivariable analysis, CV/ @entity2 above the cutoff (odds ratio, 5.57; P=0.002) remained an independent predictor of CI-AKI. The model with CV/ @entity2 demonstrated a statistically significantly net reclassification improvement of 0.23 (P=0.021) over the baseline preprocedural model, largely driven by a correct decrease in risk estimates for @entity0 not experiencing CI-AKI, with a likelihood ratio   (2) of 5.973 (P=0.029). CONCLUSIONS: CV remains a key risk factor for CI-AKI after primary percutaneous coronary intervention and our study supports the need for minimizing CV, independently from baseline preprocedural risk. A CV restricted to no more than twice and a half the baseline @entity2 might be valuable in reducing the risk of CI-AKI.

title: Renal function-adjusted contrast volume redefines the baseline estimation of contrast-induced @entity3 risk in XXXX undergoing primary percutaneous coronary intervention.

answer: @entity0


abstract: BACKGROUND: Small-cell @entity2 is an aggressive @entity1 whose rarity has prevented the development of a consensus management approach. The objective of the current study was to determine the treatment patterns and evaluate factors affecting overall survival for @entity0 with localized small-cell @entity2 . METHODS: After querying the National @entity1 Database, we identified all @entity0 diagnosed with localized small-cell @entity2 between 1998 and 2011 (n=287). Using Kaplan-Meier curves and Cox regression analyses, we assessed the effect of treatment and clinical stage on overall survival. RESULTS: Treatments included radiation therapy in 46% (n=131), chemotherapy in 38% (n=107), @entity3 deprivation therapy (ADT) in 22% (n=63) and radical prostatectomy in 13% (n=38). Median overall survival was 14.8 months. Upon multivariate analysis, local therapy (radical prostatectomy or radiation therapy) was associated with improved survival (hazard ratio (HR) 0.23, 95% confidence interval (CI) 0.14-0.38, P<0.001). Advanced clinical stage predicted worse survival among all @entity0 ( @entity4 : HR 2.83, 95% CI 1.27-6.32, P=0.011; cT4: HR 3.26, 95% CI 1.50-7.07, P=0.003) and @entity0 who received local therapy ( @entity4 : HR 4.67, 95% CI 1.41-15.44, P=0.012; cT4: HR 4.01, 95% CI 1.14-14.08, P=0.03) but not among @entity0 who received no local therapy ( @entity4 : HR 1.64, 95% CI 0.51-5.27, P=0.4; cT4: HR 2.35, 95% CI 0.74-7.48, P=0.15). Age, receipt of chemotherapy and ADT, and clinical stage T2 disease (compared with T1) did not predict survival. CONCLUSION: @entity0 with localized small-cell @entity2 have a poor overall survival. Local therapy may represent a suitable and underused modality for select @entity0 .

title: Population-based analysis of treatment modalities and survival for clinically localized small-cell XXXX .

answer: @entity2


abstract: UNASSIGNED: @entity5 is a rare, benign disease that is characterized by a local but not metastatic invasivity. In particular, @entity3 of the chest wall represent only 10-20% of all deep @entity2 . The disease occurs more often in females and has a higher incidence between puberty and the fourth decade of life. The present study reports the case of a 34-year-old female who came to our attention due to a voluminous mass in the right subcostal region. The magnetic resonance imaging of the upper abdomen confirmed the presence of a @entity1 localized between the anterior hepatic margin and the right costal plane. Through a right subcostal laparotomy, the voluminous 95*45*94-mm @entity1 was excised. Histological examination showed evidence consistent with @entity5 . The @entity0 has not shown recurrence of the disease for 4 years since the surgery. Overall, radical surgery with disease-free resection margins is the prime treatment option for this disease. Other therapeutic options, such as radiotherapy, hormonal therapy or treatment with @entity4 , can also be considered in certain cases.

title: XXXX : Clinical and therapeutic considerations based on an illustrative case.

answer: @entity5


abstract: Introduction   Numerous surgical methods are used to treat nasal obstruction due to inferior turbinate @entity2 . The primary goal of the therapy is to maximize the nasal airway for as extended a period of time as possible while minimizing therapeutic complications. Objectives   The aim of this study was to assess the effects of radiofrequency thermal ablation (RFTA) and bipolar electrocautery (BEC) on the removal of nasal obstruction in @entity0 with inferior turbinate @entity2 and on nasal mucociliary clearance (MCC). @entity0 in both groups were also evaluated in terms of postoperative morbidity. Methods   We compared the outcomes of two groups of @entity0 : those treated with RFTA (n   =   23) and those who underwent BEC (n   =   20). Nasal obstruction was graded using a visual analog scale (VAS) and MCC was measured using a @entity3 clearance test. Both measurements were performed before and 2 months after treatment. Results   Pre- and postoperative VAS scores showed significant improvement for both groups. However, MCC results did not significantly differ between two groups. Neither @entity1 nor crust formation persisted for more than 1   week in any @entity0 . Conclusion   Submucosal cauterization with preservation of the nasal mucosa and periosteum is as effective and safe as RFTA and should be considered when planning inferior turbinate interventions.

title: Radiofrequency Thermal Ablation versus Bipolar Electrocautery for the Treatment of Inferior Turbinate XXXX : Comparison of Efficacy and Postoperative Morbidity.

answer: @entity2


abstract: Introduction   The relevance of @entity1 is unquestionable. This condition affects @entity0 's quality of life and its incidence has increased over the last years. Objective   Thus, this study aims to analyze the effectiveness of subcutaneous injectable immunotherapy in cases of nasal itching, sneeze, @entity2 and nasal congestion in @entity1 @entity0 . Methods   In the present study, the same researcher analyzed the records of 281 @entity0 . Furthermore, the researchers identified allergens through puncture cutaneous tests using standardized extracts containing acari, fungi, pet hair, flower pollen, and feathers. Then, the @entity0 underwent treatment with subcutaneous specific immunotherapy, using four vaccine vials for desensitization, associated with environmental hygiene. The authors analyzed conditions of nasal itching, sneeze, @entity2 , and nasal congestion throughout the treatment, and assigned them with a score ranging from zero (0), meaning absence of these symptoms to three (3), for severe cases. The symptoms were statistically compared in the beginning, during, and after treatment. Results   In this study, authors analyzed the cases distribution according to age and the evolution of symptomatology according to the scores, comparing all phases of treatment. The average score for the entire population studied was 2.08 before treatment and 0.44 at the end. These results represent an overall improvement of    79% in symptomatology of @entity1 in the studied population. Conclusion   The subcutaneous immunotherapy as treatment of @entity1 led to a reduction in all symptoms studied, improving the quality of life of @entity0 , proving itself as an important therapeutic tool for these pathological conditions.

title: Subcutaneous Immunotherapy Improves the Symptomatology of XXXX .

answer: @entity1


abstract: PURPOSE: To review the diagnosis and treatment of @entity3 of the sternoclavicular joint in 13 @entity0 . METHODS: Records of 9 @entity0 and 4 @entity0 aged 26 to 47 (mean, 36.5) years who presented with @entity3 of the right (n=8) or left (n=5) sternoclavicular joint were reviewed. RESULTS: All 13 @entity0 had a raised erythrocyte sedimentation rate at presentation. Nine @entity0 presented with systemic symptoms including malaise, @entity2 , or loss of weight/appetite. Local symptoms included @entity6 (n=5), tenderness and non-fluctuant swelling (n=4), and discharging sinus (n=4). The mean duration of symptoms was 2.7 (range, 1-7) months. Four @entity0 had multifocal involvement of the proximal ulna (n=1), lung (n=2), and meninges (n=1). Aspiration (n=3), fine needle aspiration cytology (n=4), drainage (n=2), or curettage (n=4) of the swelling, @entity6 , or sinus was performed, and the diagnosis was confirmed by histopathology (n=8), polymerase chain reaction (n=5), or culture (n=1). Two @entity0 were diagnosed based on clinical suspicion. 11 @entity0 responded to antituberculous therapy (ATT), and symptoms resolved after 6 to 8 weeks. Two @entity0 did not respond to ATT after 3 months and were screened for immunocompromising disorders or drug resistance. Their @entity4 count and @entity4 : @entity5 ratio was low, and an immunomodulation regimen was prescribed as an adjunct to ATT. CONCLUSION: A high level of clinical suspicion is needed to diagnose @entity3 of the sternoclavicular joint in @entity0 with @entity1 /tenderness, discharging sinus, or @entity6 . A combination of histopathological and microbiological tests, and PCR can confirm the diagnosis.

title: XXXX of the sternoclavicular joint.

answer: @entity3


abstract: PURPOSE: @entity4 has been shown to be effective in treating @entity3 ( @entity3 ). In the original Phase II/III trial, however, @entity0 with @entity1 were excluded. In this study, we treated @entity0 with @entity1 @entity3 . METHODS: @entity1 was defined as a 30% increase in the area of the foveal avascular zone (FAZ) at 45 seconds on fundus @entity2 angiography. In addition, the @entity0 had diffuse foveal-involving @entity3 with a central subfield thickness (CST) of >300  m on spectral-domain optical coherence tomography. Five intravitreal @entity4 injections were given 6 weeks apart. The final study visit was 6 weeks after the fifth injection. The primary outcome was change in the size of FAZ. Secondary outcomes were change in best-corrected visual acuity (BCVA) and the change in CST. RESULTS: Thirty @entity0 were enrolled. Three were unable to complete the full course of treatment. Their outcomes were carried forward for the first part of this analysis. There was no statistically significant change in the mean size of the FAZ from baseline to the final visit. Subclassifying @entity0 as those with minimal/moderate @entity1 (16 @entity0 , FAZ area <1,000 pixels) and those with more severe @entity1 (14 @entity0 , FAZ area >1,000 pixels) also showed no statistically significant change in the mean area of the FAZ. On average, BCVA increased and CST decreased from baseline to the final visit, but these changes were not statistically significant. Using per protocol analysis on those @entity0 who completed the full course of treatment, the mean BCVA increased from 49.2 to 53.9 letters (P=0.046). CONCLUSION: In this study, intravitreal injection of @entity4 did not significantly alter the size of the FAZ in @entity0 with varying degrees of @entity1 @entity3 . There was, however, a significant improvement in mean BCVA in those who completed the treatment course.

title: Intravitreal @entity4 for the treatment of @entity1 XXXX .

answer: @entity3


abstract: PURPOSE: @entity4 has been shown to be effective in treating @entity3 ( @entity3 ). In the original Phase II/III trial, however, @entity0 with @entity1 were excluded. In this study, we treated @entity0 with @entity1 @entity3 . METHODS: @entity1 was defined as a 30% increase in the area of the foveal avascular zone (FAZ) at 45 seconds on fundus @entity2 angiography. In addition, the @entity0 had diffuse foveal-involving @entity3 with a central subfield thickness (CST) of >300  m on spectral-domain optical coherence tomography. Five intravitreal @entity4 injections were given 6 weeks apart. The final study visit was 6 weeks after the fifth injection. The primary outcome was change in the size of FAZ. Secondary outcomes were change in best-corrected visual acuity (BCVA) and the change in CST. RESULTS: Thirty @entity0 were enrolled. Three were unable to complete the full course of treatment. Their outcomes were carried forward for the first part of this analysis. There was no statistically significant change in the mean size of the FAZ from baseline to the final visit. Subclassifying @entity0 as those with minimal/moderate @entity1 (16 @entity0 , FAZ area <1,000 pixels) and those with more severe @entity1 (14 @entity0 , FAZ area >1,000 pixels) also showed no statistically significant change in the mean area of the FAZ. On average, BCVA increased and CST decreased from baseline to the final visit, but these changes were not statistically significant. Using per protocol analysis on those @entity0 who completed the full course of treatment, the mean BCVA increased from 49.2 to 53.9 letters (P=0.046). CONCLUSION: In this study, intravitreal injection of @entity4 did not significantly alter the size of the FAZ in @entity0 with varying degrees of @entity1 @entity3 . There was, however, a significant improvement in mean BCVA in those who completed the treatment course.

title: Intravitreal @entity4 for the treatment of XXXX @entity3 .

answer: @entity1


abstract: PURPOSE: @entity4 has been shown to be effective in treating @entity3 ( @entity3 ). In the original Phase II/III trial, however, @entity0 with @entity1 were excluded. In this study, we treated @entity0 with @entity1 @entity3 . METHODS: @entity1 was defined as a 30% increase in the area of the foveal avascular zone (FAZ) at 45 seconds on fundus @entity2 angiography. In addition, the @entity0 had diffuse foveal-involving @entity3 with a central subfield thickness (CST) of >300  m on spectral-domain optical coherence tomography. Five intravitreal @entity4 injections were given 6 weeks apart. The final study visit was 6 weeks after the fifth injection. The primary outcome was change in the size of FAZ. Secondary outcomes were change in best-corrected visual acuity (BCVA) and the change in CST. RESULTS: Thirty @entity0 were enrolled. Three were unable to complete the full course of treatment. Their outcomes were carried forward for the first part of this analysis. There was no statistically significant change in the mean size of the FAZ from baseline to the final visit. Subclassifying @entity0 as those with minimal/moderate @entity1 (16 @entity0 , FAZ area <1,000 pixels) and those with more severe @entity1 (14 @entity0 , FAZ area >1,000 pixels) also showed no statistically significant change in the mean area of the FAZ. On average, BCVA increased and CST decreased from baseline to the final visit, but these changes were not statistically significant. Using per protocol analysis on those @entity0 who completed the full course of treatment, the mean BCVA increased from 49.2 to 53.9 letters (P=0.046). CONCLUSION: In this study, intravitreal injection of @entity4 did not significantly alter the size of the FAZ in @entity0 with varying degrees of @entity1 @entity3 . There was, however, a significant improvement in mean BCVA in those who completed the treatment course.

title: Intravitreal XXXX for the treatment of @entity1 @entity3 .

answer: @entity4


abstract: BACKGROUND: In @entity0 with advanced-stage @entity3 ( @entity3 ), extended-field radiotherapy (efrt) is traditionally delivered by the 3-dimensional conformal (3d-crt) 4-field box technique. In recent years, the use of intensity-modulated radiotherapy (imrt) in gynecologic @entity1 has increased. We compared the delivery of efrt by the 3d-crt and contemporary imrt techniques. METHODS: After surgical staging and adjuvant chemotherapy in 38 @entity3 @entity0 , efrt was delivered by either imrt or 3d-crt. Doses to the organs at risk, side effects, and outcomes were compared between the techniques. RESULTS: Of the 38 @entity3 @entity0 , 33 were stage iiic, and 5 were stage ivb. In the imrt group, maximal doses to rectum, small intestine, and bladder were significantly higher, and mean dose to bladder was lower (p < 0.0001). Most acute gastrointestinal, genitourinary, and hematologic side effects were grade i or ii and were comparable between the groups. In long-term follow-up, only grade 1 @entity4 at 3 months was statistically higher in the imrt @entity0 . No grade iii or iv @entity2 were observed. No statistically significant differences in overall and disease-free survival or recurrence rates were observed between the techniques. CONCLUSIONS: In advanced @entity3 @entity0 , imrt is a safe and effective technique for delivering efrt to the pelvis and para-aortic region, and it is comparable to the 3d-crt 4-field box technique in both side effects and efficacy. For centres in which imrt is not readily available, 3d-crt is a valid alternative.

title: Para-aortic and pelvic extended-field radiotherapy for XXXX : dosimetric and toxicity comparison between the four-field box and intensity-modulated techniques.

answer: @entity1


abstract: BACKGROUND: We estimated the relations of sociodemographic, organizational, disease, and treatment variables with the risk of @entity3 from @entity2 ( @entity2 ) in a Quebec population-based sample of @entity0 with locally advanced @entity2 (lacrc) who underwent @entity1 resection with curative intent. METHODS: Information from medical records and administrative databases was obtained for a random sample of 633 @entity0 surgically treated for stages ii-iii rectal and stage iii @entity4 and @entity1 registry in 1998 and 2003. We measured personal, disease, and clinical management characteristics, relative survival, and through multivariate modelling, relative excess rate (rer) of @entity3 . RESULTS: The relative 5- and 10-year survivals in this cohort were 67.7% [95% confidence interval (ci): 65.8% to 69.6%] and 61.2% (95% ci: 58.3% to 64.0%) respectively. Stage T4, stage N2, and emergency rather than elective surgery affected 18%, 24% and 10% of @entity0 respectively. Those disease progression characteristics each independently increased the rer of @entity3 by factors of 2 to almost 5. Grade, vascular invasion, and @entity1 location were also significantly associated with the rer for @entity3 . Receiving guideline-adherent treatment was associated with a 60% reduction in the rer for @entity3 (0.41; 95% ci: 0.28 to 0.61), an effect that was consistent across age groups. Clear margins (proximal-distal, radial) and clinical trial enrolment were each associated with a nonsignificant 50% reduction in the rer. Of @entity0 less than 70 years of age and 70 years of age and older, 81.3% and 42.0% respectively received guideline-adherent treatment. CONCLUSIONS: This study is the first Quebec population-based examination of @entity0 with lacrc and their management, outcomes, and outcome determinants. The results can help in planning @entity2 control strategies at a population level.

title: Characteristics affecting survival after locally advanced XXXX in Quebec.

answer: @entity2


abstract: Targeting @entity0 @entity5 with the monoclonal antibody (mAb) CB.219 reduces intestinal inflammation in a @entity4 model where T cells carry @entity0 @entity5 . Here, we asked whether this mAb has adverse effects on infection control. @entity1 expressing @entity0 @entity5 on T cells (huCD2tg) were orally infected with @entity6 ( @entity6 and treated with the @entity0 @entity5 -specific mAb CB.219 in a preventive setting. The intestinal @entity6 loads in CB.219 treated @entity1 did not differ from the control group. Histologically, huCD2tg @entity1 showed moderate @entity2 that did not change with CB.219 treatment. In the ileum, CB.219 treatment reduced the protein levels of interferon-y, transforming growth factor b and @entity3 , whereas @entity8 mRNA was slightly increased. The infiltration of neutrophils, macrophages, and T cells into the ileum was unaffected by CB.219 treatment. However, CB.219 treatment decreased the numbers of @entity7 (+) regulatory T cells (Treg) in ileum and liver of huCD2tg @entity1 . This was confirmed in vitro using @entity0 peripheral blood mononuclear cells. Taken together, targeting @entity5 (+) T cells by the @entity0 @entity5 mAb CB.219 does not prevent beneficial immune reactions necessary for pathogen control. Further experiments will address gut specificity, underlying mechanisms, and general applicability of CB.219 treatment.

title: Preventive Anti-CD2 Treatment does not Impair Parasite Control in a XXXX Toxoplasmosis Model.

answer: @entity1


abstract: BACKGROUND: The prevalence of @entity3 is probably underestimated. Early detection and screening may alter the course and prognosis associated with @entity1 . We investigated the effectiveness of @entity1 function screening program and the agreement between the Global Initiative for @entity2 (GOLD) and the lower limit of normal (LLN) standard for public screening in Xi'an China. METHODS: Pulmonary function testing was conducted on volunteers recruited from eight community centers in Xi'an, China between July and August 2012. @entity0 underwent three forced vital capacity (FVC) maneuvers. The maneuver with the best FEV1 was retained. @entity0 filled out a medical history survey before undergoing pulmonary function testing. @entity0 that self-reported @entity1 on the health survey were excluded from the analysis. RESULTS: A total of 803 volunteers participated in this study. And 722 @entity0 (93.8%) did not self-report chronic @entity1 and were analyzed. Of these @entity0 , 143 subjects (19.8%) were diagnosed by GOLD standard and 134 subjects (18.6%) had obstruction with LLN definition. GOLD definition can identify more asymptomatic subjects (19.1%) with respect to LLN. GOLD definition can detect more @entity3 in elder subjects compared with young @entity0 , the difference is significant (P=0.0007). The overall agreement between the 2 methods was good: the kappa estimate was 0.822. The agreement in subjects aged 40-49, 50-59 and 60-69 years was good: the kappa estimate was 0.82, 0.936 and 0.907 respectively and the agreement in subjects aged 18-29 was inferior: the kappa estimate was only 0.555. CONCLUSIONS: Voluntary lung function screening program with GOLD standard may be a simple and effective approach to ensuring high yield detection of @entity3 in subjects aged 40-69.

title: XXXX with GOLD standard: an effective and simple approach to detect @entity3 .

answer: @entity1


abstract: BACKGROUND: The prevalence of @entity3 is probably underestimated. Early detection and screening may alter the course and prognosis associated with @entity1 . We investigated the effectiveness of @entity1 function screening program and the agreement between the Global Initiative for @entity2 (GOLD) and the lower limit of normal (LLN) standard for public screening in Xi'an China. METHODS: Pulmonary function testing was conducted on volunteers recruited from eight community centers in Xi'an, China between July and August 2012. @entity0 underwent three forced vital capacity (FVC) maneuvers. The maneuver with the best FEV1 was retained. @entity0 filled out a medical history survey before undergoing pulmonary function testing. @entity0 that self-reported @entity1 on the health survey were excluded from the analysis. RESULTS: A total of 803 volunteers participated in this study. And 722 @entity0 (93.8%) did not self-report chronic @entity1 and were analyzed. Of these @entity0 , 143 subjects (19.8%) were diagnosed by GOLD standard and 134 subjects (18.6%) had obstruction with LLN definition. GOLD definition can identify more asymptomatic subjects (19.1%) with respect to LLN. GOLD definition can detect more @entity3 in elder subjects compared with young @entity0 , the difference is significant (P=0.0007). The overall agreement between the 2 methods was good: the kappa estimate was 0.822. The agreement in subjects aged 40-49, 50-59 and 60-69 years was good: the kappa estimate was 0.82, 0.936 and 0.907 respectively and the agreement in subjects aged 18-29 was inferior: the kappa estimate was only 0.555. CONCLUSIONS: Voluntary lung function screening program with GOLD standard may be a simple and effective approach to ensuring high yield detection of @entity3 in subjects aged 40-69.

title: @entity1 with GOLD standard: an effective and simple approach to detect XXXX .

answer: @entity3


abstract: Twenty-two @entity0 with @entity8 were surgically treated between 1967 and July 1975. Five (23%) were under 1 year of age (group I) and 17 (77%) were between 2 and 24 years (group II). All @entity0 exhibited severe @entity3 and electrocardiographi (ECG) evidence of @entity7 ( @entity7 ) with strain pattern. In group II, angina was present in three cases, @entity4 and fatigue in two; the ECG indicated @entity7 in 10 cases (59%) with strain pattern in five (29%). A bicuspid aortic valve was present in 77% (17/22) of the cases; 32% had other @entity2 . Aortic valvotomy was performed on cardiopulmonary bypass in 20 cases, and with deep @entity6 and @entity5 in two. Three @entity0 under 1 month of age with associated anomalies died (hospital mortality 14%). Intraoperative average peak left ventricular-aortic systolic pressure gradient decreased from 86 to 21 mmHg (P less than 0.001). Late clinical (in all cases) and haemodynamic (26%) follow-up showed severe @entity1 in two @entity0 of group II; one of them had a second operation, the other one died three and a half years postoperatively. Results assessed on the basis of symptoms, ECG changes, aortic valve function, and/or haemodynamic findings were fair in the two surviving @entity0 . Results in group II were excellent in three, satisfactory in seven, fair in four, and poor in two cases. In @entity0 , aortic valvotomy is a palliative procedure which carries a high risk. In the older age group, early and late results are more gratifying.

title: Surgical treatment of XXXX .

answer: @entity8


abstract: UNASSIGNED: OBJECTIVE The @entity3 Foundation recommendation regarding the timing of surgical evacuation of @entity7 and @entity6 is to perform the procedure as soon as possible. Indeed, faster evacuation is associated with better outcome. However, to the authors' knowledge, no study has looked at where delays in intrahospital care occurred for @entity0 suffering from traumatic intracranial mass lesions. The goals of this study were as follows: 1) to characterize the performance of a Level 1 @entity2 center in terms of delays for @entity2 , 2) to review step by step where delays occurred in @entity0 care, and 3) to propose ways to improve performance. METHODS A retrospective review was conducted covering a 5-year period of all @entity2 . Demographic data, injury severity, @entity1 , and functional outcome data were collected. The time elapsed between @entity4 ( @entity4 ) arrival and CT imaging, between CT imaging and arrival at the operating room (OR), between @entity4 arrival and OR arrival, between OR arrival and skin incision, and between @entity4 arrival and skin incision were calculated. @entity0 were also subcategorized as either having immediate life-threatening emergencies (E0) or life-threatening emergencies (E1). The operative technique was also reviewed (standard craniotomy opening vs immediate bur hole decompression followed by craniotomy). RESULTS The study included 166 @entity0 . Of these, 58 (35%) were classified into the E0 group and 108 (64.2%) into the E1 group. The median @entity4 -to-CT delay was 54 minutes with no significant difference between the E0 and the E1 groups. The median CT-to-OR time delay was 57 minutes. The median delay for the E0 group was 39 minutes and that for the E1 group was 70 minutes (p = 0.002). The median delay from @entity4 to OR arrival for @entity0 with a CT scanning done at an outside hospital was 75 minutes. The median delay from @entity4 to OR arrival was 85 minutes for the E0 group and 127 minutes for the E1 group (p < 0.0001). The median delay from OR arrival to skin incision was 35 minutes (E0: median 27 minutes; E1: median 39 minutes; p < 0.0001). The median total time elapsed between @entity4 arrival and skin incision was 150 minutes (E0: median 131 minutes; E1: median 180 minutes). Overall, only 17% of @entity0 underwent immediate bur hole decompression, but the proportion climbed to 41% in the E0 group. A lower Glasgow @entity5 Scale score was associated with a shorter delay (p = 0.0004). CONCLUSIONS A long delay until surgery still exists for @entity0 requiring urgent mass lesion evacuation. Many factors contribute to this delay, including performing imaging and transfer to and preparation in the OR. Strategies can be implemented to reduce delays and improve the delivery of care.

title: Temporal delays in XXXX craniotomies.

answer: @entity2


abstract: OBJECTIVE: The caudal zona incerta (cZI) is a promising, clinically beneficial target for deep brain stimulation (DBS) in @entity1 ( @entity1 ). To assess whether DBS of the cZI affects the rate of @entity3 terminal dysfunction, @entity1 @entity0 with and without DBS were followed prospectively with I FP-Cit single photon emission tomography from the first diagnosis and up to 8 years. METHODS: Six @entity0 underwent DBS of the cZI during the survey period. Twenty-two @entity1 @entity0 only on pharmacotherapy served as controls. I FP-Cit and clinical assessment were performed at baseline and after 1, 3 and 5 years in all @entity0 . Ten @entity0 also underwent a I FP-Cit after 8 years. Image data were evaluated semiquantitatively. Mixed-model analysis was used to assess the relative change in I FP-Cit uptake and comparison between surgically and conservatively treated @entity1 @entity0 . RESULTS: The relative decrease in I FP-Cit uptake was more pronounced in DBS-treated @entity0 than in controls in the more affected caudate (P=0.037) and putamen (P=0.013). The annual decrease rates were higher in the less affected than the more affected putamen, and were slightly greater in DBS-treated @entity0 (4.8%, 95%confidence interval: 8.5-2.2%) than in controls (4.0%, 95% confidence interval: 5.1-3.1%). CONCLUSION: This long-term prospective study confirms that the underlying @entity2 continues despite clinical improvement in @entity1 @entity0 with DBS of the cZI. A slightly faster rate of decrease in I FP-Cit uptake in these @entity0 compared with conservatively treated @entity1 @entity0 may reflect a more aggressive form of @entity1 .

title: Long-term XXXX transporter imaging in @entity1 treated with zona incerta stimulation.

answer: @entity3


abstract: OBJECTIVE: The caudal zona incerta (cZI) is a promising, clinically beneficial target for deep brain stimulation (DBS) in @entity1 ( @entity1 ). To assess whether DBS of the cZI affects the rate of @entity3 terminal dysfunction, @entity1 @entity0 with and without DBS were followed prospectively with I FP-Cit single photon emission tomography from the first diagnosis and up to 8 years. METHODS: Six @entity0 underwent DBS of the cZI during the survey period. Twenty-two @entity1 @entity0 only on pharmacotherapy served as controls. I FP-Cit and clinical assessment were performed at baseline and after 1, 3 and 5 years in all @entity0 . Ten @entity0 also underwent a I FP-Cit after 8 years. Image data were evaluated semiquantitatively. Mixed-model analysis was used to assess the relative change in I FP-Cit uptake and comparison between surgically and conservatively treated @entity1 @entity0 . RESULTS: The relative decrease in I FP-Cit uptake was more pronounced in DBS-treated @entity0 than in controls in the more affected caudate (P=0.037) and putamen (P=0.013). The annual decrease rates were higher in the less affected than the more affected putamen, and were slightly greater in DBS-treated @entity0 (4.8%, 95%confidence interval: 8.5-2.2%) than in controls (4.0%, 95% confidence interval: 5.1-3.1%). CONCLUSION: This long-term prospective study confirms that the underlying @entity2 continues despite clinical improvement in @entity1 @entity0 with DBS of the cZI. A slightly faster rate of decrease in I FP-Cit uptake in these @entity0 compared with conservatively treated @entity1 @entity0 may reflect a more aggressive form of @entity1 .

title: Long-term @entity3 transporter imaging in XXXX treated with zona incerta stimulation.

answer: @entity1


abstract: INTRODUCTION: Air pollution exposure has been linked to @entity1 , but little is known about biomarkers modifying this association. MicroRNAs (miRNAs) control gene expression and neuronal programming. miRNA levels vary due to single nucleotide polymorphisms (SNPs) in genes processing miRNAs from precursor molecules. OBJECTIVES: To investigate whether SNPs in miRNA-processing genes are associated with cognition and modify the relationship between black @entity2 (BC), marker of traffic-related pollution, and cognitive functions. METHODS: 533 Normative Aging Study @entity0 (mean  SD 72  7years) were tested  <=4 times (mean=1.7 times) using seven cognitive tests between 1995 and 2007. We tested interactions of 16 miRNA-related SNPs with 1-year average BC from a validated land-use-regression model. We used covariate-adjusted logistic regression for low ( <=25) Mini-Mental tate Examination (MMSE) and mixed-effect regression for a global cognitive score combining six other tests. RESULTS: Global cognition was negatively associated with the homozygous minor variant of @entity9 @entity5 (-0.42SD; 95%CI: (-0.71, -0.13)) relative to the major variant. BC-MMSE association was stronger in heterozygous carriers of @entity4 @entity3 (OR=1.99; 95%CI: (1.39, 2.85)) and minor variant carriers of @entity7 @entity10 (OR=1.34; 95%CI: (1.05, 1.7)), compared to their major variant. The BC-global-cognition association was stronger in heterozygous carriers of @entity7 @entity8 (-0.10SD; 95%CI: (-0.18, -0.02)), and @entity7 @entity11 (-0.09SD; 95%CI: (-0.17, -0.02)) relative to the major variant. Blood miRNA expression analyses showed associations only of @entity3 @entity4 with miR-9 and @entity6 . CONCLUSIONS: Carriers of particular miRNA-processing SNPs had higher susceptibility to BC in BC-cognition associations, possibly due to influences on miRNA expression.

title: Long-term exposure to black XXXX , cognition and single nucleotide polymorphisms in microRNA processing genes in older @entity0 .

answer: @entity2


abstract: INTRODUCTION: Air pollution exposure has been linked to @entity1 , but little is known about biomarkers modifying this association. MicroRNAs (miRNAs) control gene expression and neuronal programming. miRNA levels vary due to single nucleotide polymorphisms (SNPs) in genes processing miRNAs from precursor molecules. OBJECTIVES: To investigate whether SNPs in miRNA-processing genes are associated with cognition and modify the relationship between black @entity2 (BC), marker of traffic-related pollution, and cognitive functions. METHODS: 533 Normative Aging Study @entity0 (mean  SD 72  7years) were tested  <=4 times (mean=1.7 times) using seven cognitive tests between 1995 and 2007. We tested interactions of 16 miRNA-related SNPs with 1-year average BC from a validated land-use-regression model. We used covariate-adjusted logistic regression for low ( <=25) Mini-Mental tate Examination (MMSE) and mixed-effect regression for a global cognitive score combining six other tests. RESULTS: Global cognition was negatively associated with the homozygous minor variant of @entity9 @entity5 (-0.42SD; 95%CI: (-0.71, -0.13)) relative to the major variant. BC-MMSE association was stronger in heterozygous carriers of @entity4 @entity3 (OR=1.99; 95%CI: (1.39, 2.85)) and minor variant carriers of @entity7 @entity10 (OR=1.34; 95%CI: (1.05, 1.7)), compared to their major variant. The BC-global-cognition association was stronger in heterozygous carriers of @entity7 @entity8 (-0.10SD; 95%CI: (-0.18, -0.02)), and @entity7 @entity11 (-0.09SD; 95%CI: (-0.17, -0.02)) relative to the major variant. Blood miRNA expression analyses showed associations only of @entity3 @entity4 with miR-9 and @entity6 . CONCLUSIONS: Carriers of particular miRNA-processing SNPs had higher susceptibility to BC in BC-cognition associations, possibly due to influences on miRNA expression.

title: Long-term exposure to black @entity2 , cognition and single nucleotide polymorphisms in microRNA processing genes in older XXXX .

answer: @entity0


abstract: UNASSIGNED: Little is known about the role of endemic ticks as vectors for bacterial and protozoan pathogens for animals and @entity0 in Madagascar and their interaction in anthropogenic habitats where @entity0 , their livestock and native Malagasy species (vectors and hosts) come into more frequent contact than in natural forest ecosystems. The aims of the study were (1) to test whether habitat degradation is associated with increased @entity2 of tortoises by ticks and (2) to investigate whether ticks carried @entity3 , @entity4 or @entity5 species that might be pathogenic for @entity0 and livestock. We studied hard ticks of two endemic Malagasy tortoises, Astrochelys radiata and Pyxis arachnoides in March and April 2013 in southwest Madagascar. Two tortoise habitats were compared, the National Park of Tsimanampetsotsa and the adjacent degraded pasture and agricultural land at the end of the wet season. Ticks were screened for protozoan and bacterial pathogens via PCR on DNA isolated from ticks using genus-specific primers. Only one out of 42 A. radiata collected from both habitats had ticks. The low prevalence did not allow further analyses of the effect of habitat degradation. Forty-two P. arachnoides were found in the anthropogenic habitat and 36 individuals in the national park. @entity2 rates of P. arachnoides differed significantly between the two study sites. Tortoises inside the park had lower tick prevalence than outside (8 of 36 (22%) versus 32 of 42 individuals (76%)) and infected animals tended to have fewer ticks inside than outside the park. All ticks collected in both habitats were adults of the ixodid tick Amblyomma chabaudi, which is supposed to be a host-specific tick of P. arachnoides. Screening for @entity4 sp. and @entity3 sp. was negative in all ticks. But all A. chabaudi ticks were infected with @entity5 africae, known to cause spotted @entity1 in @entity0 . Thus, habitat degradation seems to be linked to higher @entity2 of tortoises with ticks with possible consequences for @entity0 and their livestock.

title: Tick (Amblyomma chabaudi) XXXX of endemic tortoises in southwest Madagascar and investigation of tick-borne pathogens.

answer: @entity2


abstract: AIM OF STUDY: We examined variables associated with survival for @entity4 between 1996 and 2014. METHODS: Possible explanatory variables: birth weight, gestation, @entity3 (any or major), @entity0 (any or severe), primary @entity2 , leak, secondary oesophageal surgery, @entity5 , aortopexy, tracheostomy, gastrostomy, fundoplication, karyotype, neurological status. Variables were assessed with logistic regression and a new model assessed with Kaplan-Meier graphs. RESULTS: 104/120 (87%) babies survived. Median gestation 37weeks, 4 (3%) born before 28weeks. Mean birth weight 2.3 (SD 0.7) kg, 17 (14%) less than 1500g. Frequency (%) of explanatory variables: Major @entity3 21 (18%), any @entity3 48 (40%), @entity0 (8%), any @entity0 25 (21%), primary @entity2 105 (88%), @entity6 (13%), symptomatic @entity5 28 (23%), aortopexy 17 (14%), tracheostomy 12 (10%), @entity1 (6%), fundoplication 15 (13%), gastrostomy 30 (25%), secondary oesophageal surgery 8 (7%), abnormal karyotype 6 (5%). Multivariate analysis showed only renal (OR 0.04, 0.007 0.2) p=0.001, cardiac (OR 0.1, 0.002 0.6) p=0.01 and a primary @entity2 (OR 12.2, 1.8 81.6) p=0.01 (R2=0.48), or major cardiac (OR 0.04, 0.007 0.29) p=0.001 and severe @entity0 (OR 0.009, 0.001 0.12) p<0.001 alone were significant (R2=0.57). CONCLUSIONS: Survival is dependent on cardiac and @entity0 . Birth weight is not significant. We propose a new classification system: 1: neither severe renal nor major @entity3 , 2: either severe renal or major @entity3 , 3: severe renal and major @entity3 .

title: Statistical modelling of survival for babies with XXXX .

answer: @entity4


abstract: BACKGROUND: @entity1 ( @entity1 ) could be caused by mutations in more than 40 different genes. However, the pathogenic impact of specific mutations is in most cases unknown complicating the genetic counseling of affected families. Therefore, functional studies could contribute to distinguish pathogenic mutations and benign variants. Here, we present a novel heterozygous DES missense variant ( @entity3 ; @entity4 ) identified by next generation sequencing in a @entity1 @entity0 . DES encodes the cardiac intermediate filament protein @entity2 , which has important functions in mechanical stabilization and linkage of the cell structures in cardiomyocytes. METHODS AND RESULTS: Cell transfection experiments and assembly assays of recombinant @entity2 in combination with atomic force microscopy were used to investigate the impact of this novel DES variant on filament formation. @entity2 - @entity4 forms cytoplasmic aggregates indicating a severe intrinsic filament assembly defect of this mutant. Co-transfection experiments of wild-type and mutant @entity2 conjugated to different fluorescence proteins revealed a dominant affect of this mutant on filament assembly. These experiments were complemented by apertureless scanning near-field optical microscopy. CONCLUSION: In vitro analysis demonstrated that @entity2 - @entity4 is unable to form regular filaments and accumulate instead within the cytoplasm. Therefore, we classified DES- @entity4 as a likely pathogenic mutation. In conclusion, the functional characterization of DES- @entity4 might have relevance for the genetic counseling of affected families with similar DES mutations and could contribute to distinguish pathogenic mutations from benign rare variants.

title: Functional characterization of the novel DES mutation XXXX associated with @entity1 reveals a dominant filament assembly defect.

answer: @entity4


abstract: BACKGROUND: @entity1 ( @entity1 ) could be caused by mutations in more than 40 different genes. However, the pathogenic impact of specific mutations is in most cases unknown complicating the genetic counseling of affected families. Therefore, functional studies could contribute to distinguish pathogenic mutations and benign variants. Here, we present a novel heterozygous DES missense variant ( @entity3 ; @entity4 ) identified by next generation sequencing in a @entity1 @entity0 . DES encodes the cardiac intermediate filament protein @entity2 , which has important functions in mechanical stabilization and linkage of the cell structures in cardiomyocytes. METHODS AND RESULTS: Cell transfection experiments and assembly assays of recombinant @entity2 in combination with atomic force microscopy were used to investigate the impact of this novel DES variant on filament formation. @entity2 - @entity4 forms cytoplasmic aggregates indicating a severe intrinsic filament assembly defect of this mutant. Co-transfection experiments of wild-type and mutant @entity2 conjugated to different fluorescence proteins revealed a dominant affect of this mutant on filament assembly. These experiments were complemented by apertureless scanning near-field optical microscopy. CONCLUSION: In vitro analysis demonstrated that @entity2 - @entity4 is unable to form regular filaments and accumulate instead within the cytoplasm. Therefore, we classified DES- @entity4 as a likely pathogenic mutation. In conclusion, the functional characterization of DES- @entity4 might have relevance for the genetic counseling of affected families with similar DES mutations and could contribute to distinguish pathogenic mutations from benign rare variants.

title: Functional characterization of the novel DES mutation @entity4 associated with XXXX reveals a dominant filament assembly defect.

answer: @entity1


abstract: Diffuse @entity3 was detected in 64 @entity0 (33 males and 31 females). The diagnosis was obtained in each case from the anamnesis, the clinical findings, the chest X-ray, disturbances of the respiratory function, and from the progress of the disease. The analysis of the material produced the following parameters ranging from indicative to typical: Dry cough was reported by 70% of the @entity0 as being trouble-some. Dyspnoea on exertion and at rest existed in 95%, and gradually increased during the progress of the disease in 76,5% of these cases. On auscultation ear-near crepitant rale was heard in 78% above the affected pulmonary parts. In 62 @entity0 (96,5%) the radiogram showed disseminated streaky-reticular as well as finely to coarsely mottled infiltrations. In more than half of these cases (53%) an increase in severity was observed during the follow-up. A predominantly restrictive disturbance of ventilation existed in 85,5%. Exclusive restriction was found in 65,5%. @entity2 was detected in 92% of our cases which was especially impressive when the arterial @entity1 pressure at rest was within the normal range. The electrocardiographic findings seemed to be less unequivocal. All in all it can be stated that in the synopsis of its manifestation DIPF can be positively identified by clinical means. This fact as well as therapeutical problems are discussed taking available publications into consideration, and respective conclusions are drawn for the clinician.

title: [A contribution to the symptomatology of diffuse XXXX (DIPF) (author's transl)].

answer: @entity3


abstract: 1. Strips of @entity0 anococcygeus muscle were submaximally contracted by the addition of @entity4 to the bath fluid. 2. @entity2 , @entity11 and electrical field stimulation caused relaxation. Relaxation induced by @entity2 and field stimulation was blocked by @entity3 but only the @entity2 -induced response was inhibited by @entity6 , @entity9 and @entity8 . The responses to both @entity2 and field stimulation were resistant to @entity7 , @entity10 , and @entity5 . 3. Relatively high concentrations of @entity1 caused relaxation. 4. Histological investigation did not show any cells resembling autonomic ganglion cells. 5. It is suggested that both @entity2 and field stimulation release an inhibitory transmitter from nerve endings and that the release by @entity2 is mediated through nicotinic receptor stimulation.

title: The inhibitory response of the XXXX anococcygeus muscle.

answer: @entity0


abstract: A 12-step scheme representing initiation and development of @entity1 in the @entity2 has been devised. Simultaneous quantitative temporal measurement of the number of inflammatory cells mobilized and @entity0 volume produced as carrageenan pleurisy developed helped elucidate several of the early steps, In the pleurisy a 20-min lag phase preceded both the mobilization of neutrophils and @entity0 formation. Temporal histological studies suggested that the lag phase represents the time needed for the neutrophil chemotactic factor to be generated and/or released (steps 2 and 3) in addition to the time required for these cells to move through the walls of the capillaries into the pleural space (steps 4 and 5). The neutrophil chemotactic factor is unknown. The complement system is not involved since cobra venom factor-treated animals produced a normal @entity0 and cellular response to carrageenan in spite of severely @entity5 complement levels. The mobilized neutrophils are believed to phagocytize the carrageenan(step6). In this process lysosomal enzymes are released (step 7). Drug inhibition studies suggest that lysosomal enzymes are not the edemagenic agents in carrageenan @entity1 . In the scheme these enzymes are responsible for activation of the prostaglandin biosynthetic chain (step 8). Prostaglandin biosynthesis (step 9) leads to the release of an intermediate (step 10), as yet unidentified, which is responsible for increased tissue permeability (step 11) and @entity0 formation (step 12). @entity3 , @entity6 , @entity8 , @entity7 , and @entity9 's E1 and E2 are not deemagenic in the @entity2 pleural cavity and therefore cannot be responsible for @entity0 formation. @entity4 and @entity10 reduce the @entity0 produced by carrageenan in a dose-related manner without affecting the magnitude or the time course of neutrophil mobilization. These findings led to the concept that @entity0 formation is not the result of inflammatory cell mobilization but is rather a consequence of cellular activity, presumably phagocytosis, after mobilization.

title: Quantitative studies of the pathway to XXXX .

answer: @entity1


abstract: The usage of vertical transarticular pin fixation combined with plaster immobilization for severe @entity8 has been reviewed in 92 consecutive cases over a period of 16 years. Moderately simple in application and without a skin incision, the procedure has been found to provide efficient and reliable short-term stabilization of the ankle and @entity7 with minimal complications. A new technique is described for accurate placement of the pin and the prevention of its migration. It is a reasonable alternative treatment for certain unstable distal tibial and @entity6 when open reduction with conventional internal fixation cannot be done. In particular, the method is recommended in treating displaced @entity5 at the ankle and deltoid ligament ruptures in geriatric @entity0 . It is often useful as a salvage or last-resort procedure in unusually severe @entity8 with @entity2 . In many instances additional @entity4 to the head, thorax or abdomen may have been sustained. Thus total @entity0 care is essential and priorities must be recognized. The treatment of ankle @entity4 , furthermore, in a physiologically-aged @entity1 @entity0 is often not the same as that for similar injuries in a young healthy adult. The clinical judgement and experience of the operator is the basis for selection of the procedure. The simplest method is often the best. Pin fixation, however, is not for everyone. It should be done only by surgeons qualified to treat @entity3 and even then only for those situations in which its usage is specifically indicated.

title: Vertical transarticular pin fixation for unstable XXXX : impressions after 16 years of experience.

answer: @entity6


abstract: 1. The light chains of @entity0 immunoglobulin were allowed to dimerize in vitro on removal of the dispersing agents @entity2 or @entity1 . 2. On electrophoresis in @entity3 gel at pH8.8 the dimers yielded up to nine regularly spaced bands. This approximates to the number of electrophoretic components known to occur among the monomers. 3. Single electrophoretic components of the dimers were isolated from the gel, dissociated into monomers, and subjected as such to electrophoresis in @entity1 -containing gels. Each gave two adjacent bands. 4. Similarly, after all the light chains as monomers had been subjected to electrophoresis in @entity1 -containing gels, single electrophoretic components were isolated and allowed to dimerize. When examined now as dimers in the absence of @entity1 , each component gave two adjacent bands. 5. These findings are explicable on the following basis. (a) The dimerization of the light chains is specific, at least inasmuch as it occurs between monomers of the same electrophoretic mobilities. (b) With the buffer constant, different light chains undergo different changes in net charge on being transferred from @entity1 -containing to @entity1 -free solution; in this way two different chains of the same initial charge can acquire a charge difference of 1. 6. Experiments with Bence-Jones proteins and other homogeneous light chains gave results substantiating the conclusions (a) and (b).

title: Specific dimerization of the light chains of XXXX immunoglobulin.

answer: @entity0


abstract: A gas-chromatographic method for simultaneously measuring @entity2 ( @entity4 ) against @entity3 (A) in plasma and CSF is presented. The time course of body temperature (Tb), stereotyped behavior (St), and A and pOA levels in plasma and CSF were studied after administration of 0.6 and 1.5 mg/kg p.o. of A to @entity1 . @entity0 reached maximal value 2.5 h after A, as did levels of A in CSF. The A levels in CSF decreased steadily in the following hours and simultaneously with the levels of A in plasma. St remained elevated and began to decrease after 6.5 h. The relationship between St and amounts of A was not linear but exponential. This suggest that both A and its metabolite contributed to this effect. In fact, a linear relationship was found between St and the amounts of pOA in CSF. Body temperature had a time course similar to A plasma levels, reaching peak value after 1.5 h and declining thereafter simultaneously with A. A linear relationship was found between Tb and the amounts of A in plasma. Thus Tb seems to be a peripheral A effect related to the presence of the drug in plasma.

title: @entity0 and hyperthermia in @entity1 : correlation with the levels of @entity3 and XXXX in plasma and CSF.

answer: @entity2


abstract: A gas-chromatographic method for simultaneously measuring @entity2 ( @entity4 ) against @entity3 (A) in plasma and CSF is presented. The time course of body temperature (Tb), stereotyped behavior (St), and A and pOA levels in plasma and CSF were studied after administration of 0.6 and 1.5 mg/kg p.o. of A to @entity1 . @entity0 reached maximal value 2.5 h after A, as did levels of A in CSF. The A levels in CSF decreased steadily in the following hours and simultaneously with the levels of A in plasma. St remained elevated and began to decrease after 6.5 h. The relationship between St and amounts of A was not linear but exponential. This suggest that both A and its metabolite contributed to this effect. In fact, a linear relationship was found between St and the amounts of pOA in CSF. Body temperature had a time course similar to A plasma levels, reaching peak value after 1.5 h and declining thereafter simultaneously with A. A linear relationship was found between Tb and the amounts of A in plasma. Thus Tb seems to be a peripheral A effect related to the presence of the drug in plasma.

title: @entity0 and hyperthermia in @entity1 : correlation with the levels of XXXX and @entity2 in plasma and CSF.

answer: @entity3


abstract: A gas-chromatographic method for simultaneously measuring @entity2 ( @entity4 ) against @entity3 (A) in plasma and CSF is presented. The time course of body temperature (Tb), stereotyped behavior (St), and A and pOA levels in plasma and CSF were studied after administration of 0.6 and 1.5 mg/kg p.o. of A to @entity1 . @entity0 reached maximal value 2.5 h after A, as did levels of A in CSF. The A levels in CSF decreased steadily in the following hours and simultaneously with the levels of A in plasma. St remained elevated and began to decrease after 6.5 h. The relationship between St and amounts of A was not linear but exponential. This suggest that both A and its metabolite contributed to this effect. In fact, a linear relationship was found between St and the amounts of pOA in CSF. Body temperature had a time course similar to A plasma levels, reaching peak value after 1.5 h and declining thereafter simultaneously with A. A linear relationship was found between Tb and the amounts of A in plasma. Thus Tb seems to be a peripheral A effect related to the presence of the drug in plasma.

title: XXXX and hyperthermia in @entity1 : correlation with the levels of @entity3 and @entity2 in plasma and CSF.

answer: @entity0


abstract: A gas-chromatographic method for simultaneously measuring @entity2 ( @entity4 ) against @entity3 (A) in plasma and CSF is presented. The time course of body temperature (Tb), stereotyped behavior (St), and A and pOA levels in plasma and CSF were studied after administration of 0.6 and 1.5 mg/kg p.o. of A to @entity1 . @entity0 reached maximal value 2.5 h after A, as did levels of A in CSF. The A levels in CSF decreased steadily in the following hours and simultaneously with the levels of A in plasma. St remained elevated and began to decrease after 6.5 h. The relationship between St and amounts of A was not linear but exponential. This suggest that both A and its metabolite contributed to this effect. In fact, a linear relationship was found between St and the amounts of pOA in CSF. Body temperature had a time course similar to A plasma levels, reaching peak value after 1.5 h and declining thereafter simultaneously with A. A linear relationship was found between Tb and the amounts of A in plasma. Thus Tb seems to be a peripheral A effect related to the presence of the drug in plasma.

title: @entity0 and hyperthermia in XXXX : correlation with the levels of @entity3 and @entity2 in plasma and CSF.

answer: @entity1


abstract: OBJECTIVE: The purpose of this study was to compare operative strategies and @entity0 outcomes in @entity3 ( @entity3 ) repairs before and after the implementation of a multidisciplinary aortic surgery team. METHODS: Between May 2005 and July 2014, 101 @entity0 underwent @entity3 repair at our institution. A dedicated multidisciplinary aortic surgery team (experienced aortic surgeon, perfusionists, cardiac anesthesiologists, nurses, and radiologists) was formed in 2010. We retrospectively compared @entity3 repair outcomes in @entity0 before (2005-2009, N = 39) and after (2010-2014, N = 62) implementation of our program. Expected operative mortality was calculated using the International Registry of Acute @entity4 preoperative predictive model. RESULTS: This study demonstrated a significant reduction in operative mortality after implementation of the aortic surgery program (30.8% vs. 9.7%; P = 0.014). There was also an increase in the complexity of surgical technique and perfusion strategies with fewer @entity2 related to respiratory (P < 0.0001) and @entity1 (P = 0.034). Baseline demographics were similar, and there was no statistically significant difference in International Registry of Acute @entity4 predictive variables between the 2 groups. However, there was a 3.5-fold reduction in the observed-to-expected (O/E) operative mortality ratio. There was a 50% increase in volume with a significant number of @entity0 being admitted directly to our aortic center for @entity3 repair, thus avoiding delay in operation related to transfers from a secondary hospital. CONCLUSIONS: @entity0 outcomes are improved when the surgical treatment of @entity3 is managed by a high-volume multidisciplinary aortic surgery team.

title: Operative Strategies and Outcomes in Type A XXXX After the Enactment of a Multidisciplinary Aortic Surgery Team.

answer: @entity4


abstract: PURPOSE: @entity6 -based chemotherapy has conferred a modest but significant survival benefit and the introduction of newer drugs has led to achieve higher response rate in @entity0 with advanced @entity7 ( @entity7 ). We performed a phase II trial in order to evaluate the efficacy and @entity1 of combination chemotherapy with @entity8 ( @entity8 ) and @entity5 in advanced @entity7 . MATERIALS AND METHODS: @entity0 with previously untreated, unresectable stage IIIB or IV @entity7 with measurable lesion (s) were eligible for entry into the study. NP chemotherapy consisted of intravenous @entity8 25 mg/m2, on day 1 and 8, and intravenous @entity5 80 mg/m2 on day 1; this cycle was repeated every three weeks. RESULTS: A total of 33 @entity0 were enrolled in the study between July 1999 and Feb 2000. Of the 30 @entity0 deemed eligible for analysis, thirteen @entity0 achieved a partial response and thirteen showed a stable disease. The overall response rate was 43.3%. The median duration of response was 5.7 months (95% CI: 2.8~8.5 months). The median time to progression was 7.6 months (95% CI: 5.5~9.7 months) and the overall median survival time was 15.1 months (95% CI: 9.8~20.4 months) in the intent-to-treat analysis. Chemotherapy-related grade 3 or 4 @entity1 were @entity4 in 1.5%, @entity9 in 4.5%, @entity2 / @entity3 in 2.3%, @entity10 in 13.3%, and @entity11 in 3.3%. CONCLUSION: The combination of @entity8 and @entity5 chemotherapy seems to be active and fairly tolerable in @entity0 with advanced @entity7 .

title: Phase II Trial of @entity8 and XXXX Chemotherapy in Advanced @entity7 .

answer: @entity5


abstract: PURPOSE: @entity6 -based chemotherapy has conferred a modest but significant survival benefit and the introduction of newer drugs has led to achieve higher response rate in @entity0 with advanced @entity7 ( @entity7 ). We performed a phase II trial in order to evaluate the efficacy and @entity1 of combination chemotherapy with @entity8 ( @entity8 ) and @entity5 in advanced @entity7 . MATERIALS AND METHODS: @entity0 with previously untreated, unresectable stage IIIB or IV @entity7 with measurable lesion (s) were eligible for entry into the study. NP chemotherapy consisted of intravenous @entity8 25 mg/m2, on day 1 and 8, and intravenous @entity5 80 mg/m2 on day 1; this cycle was repeated every three weeks. RESULTS: A total of 33 @entity0 were enrolled in the study between July 1999 and Feb 2000. Of the 30 @entity0 deemed eligible for analysis, thirteen @entity0 achieved a partial response and thirteen showed a stable disease. The overall response rate was 43.3%. The median duration of response was 5.7 months (95% CI: 2.8~8.5 months). The median time to progression was 7.6 months (95% CI: 5.5~9.7 months) and the overall median survival time was 15.1 months (95% CI: 9.8~20.4 months) in the intent-to-treat analysis. Chemotherapy-related grade 3 or 4 @entity1 were @entity4 in 1.5%, @entity9 in 4.5%, @entity2 / @entity3 in 2.3%, @entity10 in 13.3%, and @entity11 in 3.3%. CONCLUSION: The combination of @entity8 and @entity5 chemotherapy seems to be active and fairly tolerable in @entity0 with advanced @entity7 .

title: Phase II Trial of @entity8 and @entity5 Chemotherapy in Advanced XXXX .

answer: @entity7


abstract: PURPOSE: @entity6 -based chemotherapy has conferred a modest but significant survival benefit and the introduction of newer drugs has led to achieve higher response rate in @entity0 with advanced @entity7 ( @entity7 ). We performed a phase II trial in order to evaluate the efficacy and @entity1 of combination chemotherapy with @entity8 ( @entity8 ) and @entity5 in advanced @entity7 . MATERIALS AND METHODS: @entity0 with previously untreated, unresectable stage IIIB or IV @entity7 with measurable lesion (s) were eligible for entry into the study. NP chemotherapy consisted of intravenous @entity8 25 mg/m2, on day 1 and 8, and intravenous @entity5 80 mg/m2 on day 1; this cycle was repeated every three weeks. RESULTS: A total of 33 @entity0 were enrolled in the study between July 1999 and Feb 2000. Of the 30 @entity0 deemed eligible for analysis, thirteen @entity0 achieved a partial response and thirteen showed a stable disease. The overall response rate was 43.3%. The median duration of response was 5.7 months (95% CI: 2.8~8.5 months). The median time to progression was 7.6 months (95% CI: 5.5~9.7 months) and the overall median survival time was 15.1 months (95% CI: 9.8~20.4 months) in the intent-to-treat analysis. Chemotherapy-related grade 3 or 4 @entity1 were @entity4 in 1.5%, @entity9 in 4.5%, @entity2 / @entity3 in 2.3%, @entity10 in 13.3%, and @entity11 in 3.3%. CONCLUSION: The combination of @entity8 and @entity5 chemotherapy seems to be active and fairly tolerable in @entity0 with advanced @entity7 .

title: Phase II Trial of XXXX and @entity5 Chemotherapy in Advanced @entity7 .

answer: @entity8


abstract: Skeletal muscle growth in two genetic lines of @entity1 that differed in total muscle content was studied at live weights of 23, 45, 68, 91, 104, 118 kg. Total physically separable muscle and cross-sectional area of the longissimus dorsi muscle were greater in the muscular than in the @entity2 genetic lines. Above 45 kg, animals in the muscular genetic line had less total separable fat than animals in the @entity2 line, but the two lines did not differ in total physically separable fat at 23 and 45 kg live weight. Hence, these two genetic lines may differ in weight at which maturity is reached as much as in inherent propensity for @entity0 . Longissimus muscle form the muscular line had more water, less protein, and less lipid than longissimus from the @entity2 line. DNA and RNA concentration, total DNA and RNA content, and RNA/DNA ratio of the pituitary and liver did not differ between the two genetic lines. Above 68 kg, longissimus from the muscular line had higher DNA and RNA concentrations than longissimus from the @entity2 line; this difference did not exist between 23 and 68 kg. RNA/DNA ratio of the longissimus muscle was greater and protein-to-DNA and protein-to-RNA ratios in longissimus were lower in the muscular than in the @entity2 line. Total DNA content @entity2 ( @entity2 ) to 2.7 (muscular)-fold between 23 and 118 kg; hence, number of muscle nuclei increases during growth. Total DNA content of physically separable muscle was greater in the muscular than in the @entity2 line and was the measurement most highly related to total muscle content.

title: Muscle growth in two genetically different lines of XXXX .

answer: @entity1


abstract: PURPOSE: The aim of this study was to evaluate the efficacy and the safety of @entity6 (Iressa(R)) as a 3rd or 4th line chemotherapy regimen in NSCLC @entity0 who are refractory to a previous chemotherapy regimen. MATERIALS AND METHODS: Twenty-five @entity0 who were refractory to previous chemotherapy were selected for this study. The eligible @entity0 had an ECOG performance status of 0 to 2, and an appropriate end organ function. @entity6 (Iressa(R))250 mg/d was orally administered until the @entity0 experienced disease progression or unacceptable @entity1 . RESULTS: Twenty-five @entity0 were analyzed. The median age of the @entity0 was 57 years. The response rate was 12.0% with partial responses in 3 @entity0 . Fourteen @entity0 (56%) remained in the stable disease state and 8 @entity0 progressed. The median overall survival was 9.0 months (95% CI 6.7~11.2). The median progression free survival was 3 months (95% CI 2.2~3.8). Hematological @entity1 of grade 3 or 4 @entity5 , @entity3 and @entity4 were absent. Non-hematological @entity1 were grade 2 or 3 skin rashes in 10 (40.0%) @entity0 and 1 (4.0%) @entity0 and grade 3 @entity2 in 3 (12.0%) @entity0 . No @entity0 failed to continue chemotherapy due to any drug-related adverse events. CONCLUSION: The results suggest that @entity6 (Iressa(R)) monotherapy is effective and tolerable as a 3rd or 4th line salvage treatment for NSCLC @entity0 refractory to previous chemotherapy regimens.

title: The Effect of XXXX (Iressa(R)) in the Treatment of Refractory Non Small Cell Lung Cancer.

answer: @entity6


abstract: PURPOSE: Best clinical management of severe @entity1 is still a subject of debate. Most surgical teams consider severe @entity1 as an indication for emergency surgery. But, under certain circumstances, conservative management is feasible, avoids the need for gastrectomy, and has a low mortality rate. Postponed reconstructive surgery is usually performed several months after caustic ingestion to restore intestinal continuity or to treat stricture sequelae. This study aimed to investigate long-term nutritional and quality of life (QoL) outcomes after reconstructive surgery for high-grade esophageal and gastric @entity1 . METHODS: Twenty-one @entity0 were assessed for biological and nutritional parameters, physical findings, and quality of life surveys at least 25  months after reconstructive surgery among @entity0 who have required emergency surgery (n   =   10) and @entity0 who did not undergo emergency surgery (n   =   11). RESULTS: After median follow-up of 74  months (after caustic ingestion) and 67  months (after reconstructive surgery), @entity0 who avoided emergency surgery experienced faster oral diet resumption (49 vs. 157  days, p   =   0.004), less @entity2 (0.3 vs. 20  kg, p   =   0.002), greater body fat percentage (22 vs. 18  %, p   =   0.046), better nutritional and physical status (SF12 PCS 51 vs. 43, p   =   0.036), and less trouble eating (EORTC QLQ-OG 25 31 vs. 56, p   =   0.01). CONCLUSIONS: Our study is the first to evaluate long-term nutritional and QoL outcomes, following severe @entity1 . It demonstrates better long-term nutritional outcomes and QoL in @entity0 suitable for initial conservative management. These results support full functional recuperation of spared organs, even severely burned. In the absence of clinical or biological signs necessitating immediate surgery, conservative management should be advocated.

title: Conservative management of severe XXXX during acute phase leads to superior long-term nutritional and quality of life (QoL) outcome.

answer: @entity1


abstract: Cumulated evidence indicates that @entity2 ( @entity2 ) is significantly involved in @entity1 progression. Recent studies yielded conflicting results regarding the association between serum @entity2 and @entity3 ( @entity3 ). To clarify this correlation, we performed a meta-analysis. Potential relevant studies were identified by searching the following databases: PubMed, Embase, CINAHL, Science Citation Index database, the Cochrane Library, Current Contents Index, Chinese Biomedical, the Chinese Journal Full-Text, and the Weipu Journal. Data from eligible studies were extracted and included into the meta-analysis using a random-effect model. Standardized mean differences (SMDs) and 95% confidence intervals (CIs) were used to assess the association between serum @entity2 levels and @entity3 . Thirteen case-control studies, including 707 @entity3 cases and 442 healthy controls, were selected for the meta-analysis. The results indicate a significantly higher serum @entity2 level in @entity0 with @entity3 than that in the controls (cases vs controls: @entity4 = 1.31, 95%CI = 0.84-1.78, P < 0.001). Ethnicity-subgroup analysis indicated a higher @entity2 level in Asian and Caucasian @entity0 with @entity3 (all P < 0.05). This meta-analysis indicates that increased serum @entity2 level correlates with the development of @entity3 , suggesting that @entity2 may present a clinical value in reflecting the progression of @entity3 . Further larger sample size studies are warranted.

title: Serum matrix metalloproteinases-3 levels in @entity0 with XXXX .

answer: @entity3


abstract: Cumulated evidence indicates that @entity2 ( @entity2 ) is significantly involved in @entity1 progression. Recent studies yielded conflicting results regarding the association between serum @entity2 and @entity3 ( @entity3 ). To clarify this correlation, we performed a meta-analysis. Potential relevant studies were identified by searching the following databases: PubMed, Embase, CINAHL, Science Citation Index database, the Cochrane Library, Current Contents Index, Chinese Biomedical, the Chinese Journal Full-Text, and the Weipu Journal. Data from eligible studies were extracted and included into the meta-analysis using a random-effect model. Standardized mean differences (SMDs) and 95% confidence intervals (CIs) were used to assess the association between serum @entity2 levels and @entity3 . Thirteen case-control studies, including 707 @entity3 cases and 442 healthy controls, were selected for the meta-analysis. The results indicate a significantly higher serum @entity2 level in @entity0 with @entity3 than that in the controls (cases vs controls: @entity4 = 1.31, 95%CI = 0.84-1.78, P < 0.001). Ethnicity-subgroup analysis indicated a higher @entity2 level in Asian and Caucasian @entity0 with @entity3 (all P < 0.05). This meta-analysis indicates that increased serum @entity2 level correlates with the development of @entity3 , suggesting that @entity2 may present a clinical value in reflecting the progression of @entity3 . Further larger sample size studies are warranted.

title: Serum matrix metalloproteinases-3 levels in XXXX with @entity3 .

answer: @entity0


abstract: A series of 100 therapeutic abortions by @entity0 is reported. This method of @entity0 with a transverse low segment incision just above the internal os of the cervix was first described by Fuchs in 1939. The important advantage of this method is complete avoidance of the uterine cervix. With this method a therapeutic @entity4 after the tenth week of gestation and in a few cases, up to the 20th week of gestation can be accomplished by a fast one stage technique with few side effects. The method is considered to be superior to the injection methods and the two stage procedures. With skill in vaginal operative techniques, this method can be used in any gynaecological department as a routine method. In this series, 28 cases had concomitant tubal ligations. There were two subsequent pregnancies. Complications were one uterine perforation during the curettage requiring laparotomy and suture. There was one laceration of the trigon of the bladder requiring suture. There were 2 cases of @entity1 . There were 6 inflammatory reactions in the perimetria of which two required administration of antibiotics. There was superficial @entity2 in one case. And there was a severe @entity3 in one case of a missed @entity4 at 5 months gestation.

title: [The vaginal transverse low segment hysterotomy for second trimester therapeutic XXXX (author's transl)].

answer: @entity4


abstract: BACKGROUND: Pump @entity3 is a major adverse event in @entity0 supported with a left ventricular assist device (LVAD). Treatment approaches include device exchange, lytic therapy, or augmentation of anticoagulation or antiplatelet therapy. The optimal strategy in the HeartWare HVAD Ventricular Assist System (HeartWare, Framingham, MA) is uncertain, and because few large studies have examined differing treatment outcomes, we have reviewed findings from the Mechanical Circulatory Support Research Network registry. METHODS: Between March 2009 and August 2014, 175 @entity0 (133 male) underwent implantation of the HeartWare HVAD at institutions that comprise the Mechanical Circulatory Support Research Network. Median age at implant was 59 years (range, 18-76 years). Follow-up was available in all @entity0 for a median of 6 months (maximum, 61 months) and for a total of 163 @entity0 -years of support. There were 36 pump @entity3 (using Interagency Registry for Mechanically Assisted Circulatory Support criteria) in 21 @entity0 for a total event rate of 0.22 events/ @entity0 -year of support; 13 @entity0 had 1 event, 4 had 2, 2 had 3, 1 had 4, and 1 had 5. The median time to the first @entity3 was 6.4 months, and to each subsequent @entity3 was 4, 3, 2, and 2 months, respectively. Primary treatment success was defined as the @entity0 remaining alive and within the first 30 days of the initial treatment be free from @entity1 , recurrence of pump @entity3 , device exchange, or urgent transplantation (United Network of Organ Sharing Status 1A). Medical treatment was defined as tissue plasminogen activator, @entity4 plus glycoprotein IIb/IIIa inhibitor, or @entity4 alone, not followed by surgical treatment within 72 hours. RESULTS: Initial medical treatment was used in 29 episodes (tissue plasminogen activator in 24, @entity4 alone in 4, and @entity4 plus glycoprotein IIb/IIIa in 1) and surgical (device exchange) in 7. Medical treatment was successful in 14 of 29 episodes (48%). Complications of medical treatment included @entity1 in 6 @entity0 (21%), need for urgent device exchange/transplant in 6 (21%), and @entity2 in 3 (10%). Surgical treatment was successful in all 7 @entity0 (100%). No significant early complications or early @entity2 occurred after device exchange. CONCLUSIONS: In this large multicenter analysis, we observed that medical therapy, as the initial treatment strategy for HeartWare HVAD @entity3 , is associated with low success (48%) and a significant risk of @entity1 (21%) and @entity2 (10%). However, initial treatment with device exchange was uniformly successful and not associated with significant early morbidity or @entity2 . Although the optimal treatment approach for HeartWare HVAD pump @entity3 remains undecided, these data do not support the routine use of medical therapy as an initial treatment strategy.

title: Treatment of device XXXX in the HeartWare HVAD: Success and outcomes depend significantly on the initial treatment strategy.

answer: @entity3


abstract: PURPOSE: Primary retroperitoneal @entity3 (PRMCa) is a rare @entity1 . Prognosis and optimal management are not well established. In view of a case managed in our Centre, we performed a systematic review and meta-analysis. METHOD: Systematic review of medical electronic databases for published data (1950-12/10/2015). No RCTs identified. Individual @entity0 data detracted from case reports and case series were analysed RESULTS: In total, 73 female and 5 male cases of PRMCa identified including our case. Median age at diagnosis was 42.0  years (range 18-86  years), with @entity0 being significantly younger than @entity0 at diagnosis (42.0  years versus 62.2  years, p  =  0.005). A palpable abdominal mass and @entity2 were the most common presentations in 42.9 and 23.8  % of cases, respectively. Twenty-six @entity0 were <38  years old. There were 16 @entity0 <38  years old that had surgical data reported, of which 14 underwent fertility-sparing surgery with excision of the mass. Adjuvant chemotherapy was given in 24.1  % (13/72) @entity0 . Follow-up ranged from 1 to 130  months with a median of 15  months. Of the 57 cases that had follow-up reported, recurrence occurred in 23 cases (40.4  %) within a median of 8  months from diagnosis. Median disease-free survival was 15  months (range 1-130  months). Of the @entity0 who recurred, 14 died of their disease giving 1, 2 and 5-year disease-specific survival rates of 85.9, 80.7 and 75.4  %, respectively. CONCLUSION: PRMCa are rare and potentially aggressive @entity1 that often occur in young @entity0 . @entity1 , adequate staging and adjuvant chemotherapy needs to be considered.

title: Primary retroperitoneal XXXX (PRMCa): a systematic review of the literature and meta-analysis.

answer: @entity3


abstract: OBJECTIVE: @entity5 kinase inhibitors (TKIs) of the @entity4 ( @entity4 ) have been reported to be effective in the treatment of esophageal and esophagogastric junction @entity1 . The aim of this study was to detect the frequency of @entity4 mutation and expression in Chinese @entity0 with esophageal, esophagogastric junction and @entity2 , and to clarify the value of @entity4 mutation and expression in predicting the efficacy of TKI in the treatment of these @entity1 . METHODS: In this study, 180 @entity1 samples with histologically confirmed @entity3 (39 cases), @entity1 of the esophagogastric junction (92 cases) and @entity2 (49 cases) were collected. Twenty-nine different @entity4 mutations in exons 18-21 were assessed by real-time PCR-optimized oligonucleotide probe method. @entity4 protein expression was evaluated by immunohistochemistry (IHC) in 89 @entity1 samples. RESULTS: The mutation analysis for @entity4 (exons 18-21) showed no mutations in any of the hotspots of the gene in the 180 @entity1 samples analyzed. @entity4 expression was negative in 12 @entity1 samples, 1+ in 31 @entity1 samples, 2+ in 24 @entity1 samples, and 3+ in 22 @entity1 samples. @entity4 expression was 2+ or 3+ in 12 (92.3%) of the 13 esophageal @entity6 , 29 (47.5%) of the 61 esophagogastric junction @entity1 , and 5 (33.3%) of the 15 @entity2 . CONCLUSIONS: Our results indicate that @entity4 mutation in exons 18-21 is absent in the examined samples of esophageal, esophagogastric junction and @entity2 . More studies are warranted to explore the predictive biological markers for the therapeutic response to @entity4 TKI.

title: [Detection and significance of XXXX mutation in esophageal, esophagogastric junction and @entity2 ].

answer: @entity4